Home » Archive by Category


San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Thermo Fisher Scientific Announces Its Ion PGM Dx Next Generation Sequencing System Is Now CE-Marked For In Vitro Diagnostic (IVD) Use

October 16, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific today announced the successful CE-IVD registration of its new Ion PGM Dx System for sale in European countries. The Ion PGM Dx System was developed using the proven Ion Torrent next generation sequencing (NGS) technology, currently used to produce hundreds of thousands of tests in clinical research laboratories each year to uncover meaningful…

Is Pursuing A Ph.D. Worth It? 7,200 UC Ph.D. Alumni Respond

October 16, 2014 – 5:00 am | Edit Post

Quidel Corporation Receives FDA Clearance For Its Lyra Molecular PCR Assay For The Detection Of Human Parainfluenza Viruses (HPIV), Types 1, 2 And 3

October 16, 2014 – 5:00 am | Edit Post

SAN DIEGO, CA–(Marketwired – October 15, 2014) – Highlighted Links Quidel DHI

Biomerica Reports First Quarter Results

October 16, 2014 – 5:00 am | Edit Post

IRVINE, CA–(Marketwired – October 16, 2014) – Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced financial results today for the first fiscal quarter ended August 31, 2014.Fiscal 2015 first quarter net sales for…

Two New Clinical Studies Show Masimo Corporation Noninvasive Hemoglobin (SpHb) Demonstrated Similar Precision As Hemoglobin From Point Of Care Devices

October 16, 2014 – 5:00 am | Edit Post

IRVINE, CA–(Marketwired – October 16, 2014) – Masimo (NASDAQ: MASI) announced two new studies today that showed that noninvasive hemoglobin (SpHb®) demonstrated similar accuracy as hemoglobin measured by invasive hemoglobin analyzers when both SpHb and the invasive…

Illumina Admits First Startup Accelerator Class

October 15, 2014 – 12:47 pm | Edit Post

Bioinformatics giant Illumina (NASDAQ: ILMN) is getting into the accelerator game, along with other players in the life sciences and other fields. On Wednesday it announced the first three startups…

[[Click headline to continue reading.]]

Three Companies Selected for Inaugural Illumina Accelerator

October 15, 2014 – 12:05 pm | Edit Post

Illumina Inc. announced the selection of three startup companies for the inaugural Illumina Accelerator funding cycle. The companies are Encoded Genomics Inc., EpiBiome Inc., and Xcell Biosciences Inc.

Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Human Parainfluenza Viruses (HPIV), Types 1, 2 and 3

October 15, 2014 – 11:00 am | Edit Post

SAN DIEGO, CA–(Marketwired – Oct 15, 2014) – Quidel Corporation ( NASDAQ : QDEL ), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Lyra Parainfluenza Assay, a real-time PCR test for the qualitative detection and identification of human parainfluenza virus (HPIV) infections for virus types 1, 2, or 3 viral RNA extracted from nasal swab and nasopharyngeal swab specimens.

San Diego’s Flourishing Industrial Biotech Sector Provides the Backdrop for BIO’s 2014 Pacific Rim Summit on Industrial Biotech & Bioenergy

October 15, 2014 – 6:38 am | Edit Post

WASHINGTON–(BUSINESS WIRE)–San Diego-based industrial biotech companies continue to deliver next generation products and innovative technology solutions, many of which will be highlighted during the 2014 BIO Pacific Rim Summit.

Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial Launch

October 15, 2014 – 5:30 am | Edit Post

SAN DIEGO, Oct. 15, 2014 /PRNewswire/ — Orexigen Therapeutics, Inc. (Nasdaq:OREX) today announced it has earned a $70 million milestone payment from partner Takeda Pharmaceuticals related to the shipment of Contrave® (naltrexone HCI and bupropion HCI extended release) to pharmacy wholesalers in preparation for commercial launch. The milestone is payable within 30 days of invoice. On October 7, Orexigen received from Takeda $30 million in milestone payments that were earned in September with the approval of Contrave by the United States Food and Drug Administration and the delivery to Takeda of Contrave launch supplies. Orexigen expects to end 2014 with approximately $190 million in cash, cash equivalents and marketable securities.